Drug Lucentis May Fight Diabetic Eye Disease
Title: Drug Lucentis May Fight Diabetic Eye DiseaseCategory: Health NewsCreated: 11/13/2015 12:00:00 AMLast Editorial Review: 11/16/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 16, 2015 Category: Endocrinology Source Type: news
Ranibizumab Deemed Major Advance for Diabetic Retinopathy Ranibizumab Deemed Major Advance for Diabetic Retinopathy
Ranibizumab was noninferior to panretinal photocoagulation for visual acuity in patients with proliferative diabetic retinopathy, according to 2-year results of the Protocol S Study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Injection instead of laser may be viable treatment option for diabetic retinopathy
Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at two years, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 14, 2015 Category: Science Source Type: news
Drug Lucentis May Fight Diabetic Eye Disease
Government-funded study finds injected medicine beats laser therapy for form of retinopathy (Source: WebMD Health)
Source: WebMD Health - November 14, 2015 Category: Consumer Health News Source Type: news
Diabetic blindness could be reversed with eye injection
Injecting the drug ranibizumab into the eyes of diabetics improved their sight and prevented further deterioration (Source: Telegraph Health)
Source: Telegraph Health - November 14, 2015 Category: Consumer Health News Tags: injection ranibizumab blind drugs blindness diabetes Source Type: news
Drug Lucentis May Fight Diabetic Eye Disease
Government-funded study finds injected medicine beats laser therapy for form of retinopathy
Source: HealthDay
Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 14, 2015 Category: Consumer Health News Source Type: news
Lucentis Effective for Proliferative Diabetic Retinopathy
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years.
Language
English (Source: News from NEI)
Source: News from NEI - November 11, 2015 Category: Opthalmology Authors: Jason Source Type: news
Eylea vs Lucentis for Treatment-Naive Neovascular AMDEylea vs Lucentis for Treatment-Naive Neovascular AMD
A new study compares outcomes between these two drugs in previously untreated patients with neovascular AMD. How do they stack up? BMC Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 5, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Anti-VEGF Therapy Before Steroids for Retinal Vein OcclusionAnti-VEGF Therapy Before Steroids for Retinal Vein Occlusion
Aflibercept and ranibizumab should be the first-line options in the treatment of central retinal vein occlusion, according to one small study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
'Encouraging' Real-life Data on Ranibizumab in Wet AMD'Encouraging' Real-life Data on Ranibizumab in Wet AMD
Most patients with age-related macular degeneration (AMD) in a 'real-life' study maintained their vision or continued to improve after 5 years of treatment with ranibizumab. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 18, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Effectiveness and Costs of Bevacizumab vs Ranibizumab in DMEEffectiveness and Costs of Bevacizumab vs Ranibizumab in DME
A new head-to-head trial compares the efficacy and economic value of these two anti-VEGF agents for DME. Which one has the edge? BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Intas cuts Razumab supplies after adverse eye reactions
Razumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25 per cent cheaper than the innovator drug marketed by Novartis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2015 Category: Pharmaceuticals Source Type: news
Ranibizumab for Neovascular AMD in Eyes With Good VisionRanibizumab for Neovascular AMD in Eyes With Good Vision
Starting ranibizumab treatment for neovascular AMD in eyes with good baseline visual acuity may provide additional benefits to visual outcomes. The British Journal of Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - August 20, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Endophthalmitis Risk No Greater With Avastin Than Lucentis Endophthalmitis Risk No Greater With Avastin Than Lucentis
FDA-proposed restrictions on the ophthalmic use of bevacizumab through compounding pharmacies may be unnecessary, researchers find. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Eye Infection Risk Similar for Avastin, Lucentis Injections (CME/CE)
(MedPage Today) -- Calls FDA guidance limiting ophthalmic bevacizumab compounding into question (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 14, 2015 Category: Geriatrics Source Type: news
